Jubashi Takashi, Tomokawa Takuya, Hara Kazusato, Horai Yoshiro, Kawakami Atsushi
Department of Rheumatology, Sasebo City General Hospital, Japan.
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Intern Med. 2025 May 1;64(9):1427-1433. doi: 10.2169/internalmedicine.4389-24. Epub 2024 Oct 11.
We herein report three cases of microscopic polyangiitis (MPA). Two patients were administered avacopan in combination with glucocorticoid (GC), whereas one patient was treated with avacopan monotherapy; none of the patients were co-administered either rituximab or cyclophosphamide. The doses of GC were successfully reduced after the introduction of avacopan in the two patients, and the serum C-reactive protein levels decreased in the patient treated with avacopan monotherapy. Avacopan may therefore be effective either in combination with GC or as monotherapy, even for patients at a high risk of developing adverse effects when administered rituximab or cyclophosphamide.
我们在此报告三例显微镜下多血管炎(MPA)病例。两名患者接受阿伐考泮联合糖皮质激素(GC)治疗,而一名患者接受阿伐考泮单药治疗;所有患者均未同时使用利妥昔单抗或环磷酰胺。在两名患者中引入阿伐考泮后,GC剂量成功降低,接受阿伐考泮单药治疗的患者血清C反应蛋白水平下降。因此,阿伐考泮联合GC或作为单药治疗可能有效,即使对于使用利妥昔单抗或环磷酰胺时有发生不良反应高风险的患者也是如此。